PhysioAssist’s Post

New Topline Efficacy Data from the enVVeno Medical VenoValve® Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 https://bit.ly/4aQUeII #CVI #ChronicVenousInsufficiency #VenousDisease

We are back with 'Lessons from the SV95C qualification Series'. In 2023, Sysnav and its partners qualified SV95C, the first digital primary endpoint to the European Medicines Agency (EMA). In the next few months, we'll share our biggest takeaways from the qualification. 🤝 Lesson 2: It takes a village Creating meaningful endpoints requires interaction between physicians, engineers, patient associations, and regulators.  Digital endpoints should be: 👉 Meaningful for patients 👉 Used by clinicians 👉 Trusted by regulators The SV95C EMA qualification is the result of collaboration with University of Oxford, Roche, Parent Project Muscular Dystrophy, Muscular Dystrophy UK, World Duchenne Organization, and many others.

Laboratory diagnostic testing is pivotal in guiding clinical decisions for patient treatment and clinical trial outcomes. And, access to both routine and specialized testing can significantly impact the success of your trial protocol. Download our Top Takeaways for Preparing and Analyzing Lab Samples to ensure you’re meeting the analytical requirements of your clinical trial protocol by: ✅ Matching your central lab partner to your protocol needs ✅ Staying current on lab testing innovation ✅ Considering protocol design to reduce patient and site burden ✅ Understanding new lab capabilities that can drive trial success ➡️ https://lnkd.in/erv-ixDK #ClinicalTrial #CentralLab #LabConnect #TopTakeaways

#ClinicalTrial #CentralLab #LabConnect #TopTakeaways Laboratory diagnostic testing is pivotal in guiding clinical decisions for patient treatment and clinical trial outcomes. And, access to both routine and specialized testing can significantly impact the success of your trial protocol. Download our Top Takeaways for Preparing and Analyzing Lab Samples to ensure you’re meeting the analytical requirements of your clinical trial protocol by: ✅ Matching your central lab partner to your protocol needs ✅ Staying current on lab testing innovation ✅ Considering protocol design to reduce patient and site burden ✅ Understanding new lab capabilities that can drive trial success ➡️ https://lnkd.in/erv-ixDK

Register for this webinar to learn how configurable solutions are transforming study launches by reducing coding errors, enhancing consistency across studies and enabling the acquisition of more reliable data. This not only streamlines the process but also makes it more cost-effective compared to traditional customized solutions that require complex and lengthy implementations.

ON-DEMAND // View the second installment of our webinar series with Precision For Medicine, focusing on optimizing immunohistochemistry (IHC) validation and regulatory strategies. This session explores in-depth the essential validation and regulatory strategies for IHC, providing crucial insights into the regulatory landscape and validation processes necessary for successful clinical trials. Watch it here: https://lnkd.in/gS3WemA9

*Time change: Tuesday 9th Jan, 4 PM PST* We’re excited to present at the upcoming J.P. Morgan 42nd Annual Healthcare Conference taking place in San Francisco next week. Emanuele Ostuni will describe our novel #alpha #radioligandtherapy based on the ideal isotope, #Pb212, and its associated manufacturing approach to transform patient care. We look forward to a healthy conversation on the key drivers of efficacy in #radiopharmaceuticals, and on the importance of distributed manufacturing. #JPM24 #nuclearmedicine

Going to CRT - Cardiovascular Research Technologies? Thomas E. Waggoner, DO, FACC, FSCAI, FSVM, RPVI will be presenting 30-day data from the DurAVR™ THV US Early Feasibility Study (EFS), and Rishi Puri will be presenting the latest DurAVR THV FIH study results and an analysis of the EFS data. Mark your calendars! #CRT2024 Can’t attend? Sign up for clinical data updates here: https://lnkd.in/gur9JPeX DurAVR™ INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

Join us at ADLM to learn about CgA and how automation improves testing performance

We're presenting three abstracts at #ARVO2024! The Exonate team will be presenting our exciting #clinicaltrial data from the recent Phase Ib/IIa mild NPDR/DME (NCT04565756) clinical study which assessed the safety, tolerability and signals of biological response to EXN407, as well as a digital strategy for #patient enrolment, and additional information on our lead candidate EXN407. More information below ⬇ #Ophthalmology #MacularEdema